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Abstract
Objective: Nocturnal frontal lobe epilepsy (NFLE) can be sporadic or autoso-
mal dominant; some families have nicotinic acetylcholine receptor subunit
mutations. We report a novel autosomal recessive phenotype in a single family
and identify the causative gene. Methods: Whole exome sequencing data was
used to map the family, thereby narrowing exome search space, and then to
identify the mutation. Results: Linkage analysis using exome sequence data
from two affected and two unaffected subjects showed homozygous linkage
peaks on chromosomes 7, 8, 13, and 14 with maximum LOD scores between
1.5 and 1.93. Exome variant filtering under these peaks revealed that the
affected siblings were homozygous for a novel splice site mutation (c.93+2T>C)
in the PRIMA1 gene on chromosome 14. No additional PRIMA1 mutations
were found in 300 other NFLE cases. The c.93+2T>C mutation was shown to
lead to skipping of the first coding exon of the PRIMA1 mRNA using a mini-
gene system. Interpretation: PRIMA1 is a transmembrane protein that anchors
acetylcholinesterase (AChE), an enzyme hydrolyzing acetycholine, to membrane
rafts of neurons. PRiMA knockout mice have reduction of AChE and accumu-
lation of acetylcholine at the synapse; our minigene analysis suggests that the
c.93+2T>C mutation leads to knockout of PRIMA1. Mutations with gain of
function effects in acetylcholine receptor subunits cause autosomal dominant
NFLE. Thus, enhanced cholinergic responses are the likely cause of the severe
NFLE and intellectual disability segregating in this family, representing the first
recessive case to be reported and the first PRIMA1 mutation implicated in
disease.
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Introduction
Nocturnal frontal lobe epilepsy (NFLE) is characterized
by frequent, sometimes violent, and often brief seizures at
night, that usually commence during childhood. It can
arise sporadically or be inherited in an autosomal domi-
nant fashion (ADNFLE).1 Clinical features associated with
nocturnal seizures include vocalizations, complex and
often violent automatisms, and ambulation, making the
condition sometimes difficult to distinguish from para-
somnias.2 Electroencephalography (EEG) is often unre-
vealing, and magnetic resonance imaging (MRI) typically
shows no lesions in patients with NFLE. In some cases
NFLE is accompanied by intellectual disability and psy-
chiatric disorders, the pathogenic mechanisms of which
remain unclear.2–4
A minority of ADNFLE cases are due to mutations in
three genes (CHRNA2, CHRNA4 and CHRNB2) that
encode the a2, a4 and b2 subunits of the neuronal nico-
tinic acetylcholine receptor.5–7 More recently, mutations
in the sodium-activated potassium channel KCNT18 were
shown to cause a small number of severe familial and
sporadic cases. Mutations in the mTOR signaling protein
DEPDC5 may also present with NFLE, including in 13%
of families in one study.9–12 The etiology of other familial
NFLEs remain to be elucidated, but additional genes are
expected to be involved. Gain of function of mutated nic-
otinic cholinergic receptors appears to be the common
mechanism in in vitro studies of human mutations.5,13
Based on this electrophysiological data, and the genetic
data above, other proteins of the cholinergic nervous sys-
tem may be involved in the pathogenesis of NFLE.
Herein we report a small Australian family of Italian
origin segregating autosomal recessive NFLE (ARNFLE)
and intellectual disability. Using a methodology we
recently reported14 we performed linkage analysis with
whole exome sequencing data to map the disorder to
multiple genomic loci, and then, using the same sequence
data, we identified the causative gene mutation on chro-
mosome 14. The mutated gene, PRIMA1, encodes a pro-
line-rich transmembrane protein that efficiently
transforms secreted acetylcholinesterase (AChE) into an
enzyme anchored on the outer cell surface.
Materials and Methods
Family and sporadic cases
A two-generation Australian family of Italian origin with
NFLE and intellectual disability was studied (Fig. 1). The
Human Research Ethics Committee of Austin Health,
Melbourne, Australia, approved this study. Informed con-
sent was obtained from living subjects or their relatives.
For re-sequencing experiments, 300 sporadic patients
diagnosed with NFLE were collected and phenotyped
including 212 cases with Italian ancestry.
Patient samples
Whole blood was obtained and genomic DNA extracted
using a Qiagen QIAamp DNA Maxi Kit (Valencia, CA).
For individual I:2, who died of breast cancer, paraffin-
embedded breast tissue was available for genotyping. The
paraffin was removed by treatment with xylene and DNA
extracted using phenol chloroform as described previ-
ously.15 Fresh whole blood samples were obtained from
affected individual II:3 and her unaffected brother II:1 to
generate a lymphoblastoid cell line (LCL) for transcript
studies.
Whole exome sequencing
Exome sequencing was performed using 3 lg of venous
blood-derived genomic DNA from each of four family
members (I:1, II-1, II-2 and II-3; Fig. 1). Genomic DNA
was sonicated to approximately 200 base pair (bp) frag-
ments and adaptor-ligated to make a library for paired-
end sequencing. Following amplification and barcoding,
the libraries were hybridized to biotinylated complemen-
tary RNA oligonucleotide baits from the SureSelect
Human All Exon 50 Mb Kit (Agilent Technologies,
Santa Clara, CA) and purified using streptavidin-bound
Figure 1. Pedigree of Australian family. Two-generation Australian
family of Italian origin segregating ARNFLE (autosomal recessive
nocturnal frontal lobe epilepsy) and intellectual disability showing
genotypes of the PRIMA1 c.93+2 nucleotide. Open symbols
unaffected; shaded symbols affected; double line consanguineous
event; diagonal line deceased. A breast tissue sample was available
from individual I:2 for genotyping by Sanger sequencing; blood
samples were obtained from the other family members (I:1, II-1, II-2
and II-3), and these samples were exome sequenced.
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magnetic beads as described previously.16 Amplification
was conducted prior to sequencing on the Illumina HiSeq
2000 system (San Diego, CA). The exome design covers 50
megabases of human genome that includes all exons anno-
tated in the GENCODE project (reference annotation for
the ENCODE project; Wellcome Trust Sanger Institute)
and consensus CDS database (CCDS – March 2009) as well
as 10 bp of flanking sequence for each targeted region and
small noncoding RNAs from miRBase (http://www.mirba-
se.org/) (v.13) and Rfam (http://rfam.xfam.org/).
Whole exome analysis and linkage mapping
Exome sequencing reads were aligned with Novoalign ver-
sion 3.02.00 (http://www.novocraft.com/) to the human
genome assembly with ambiguous SNPs (hg19 dbSNP132-
masked, UCSC Genome Browser). PCR duplicates were
removed using MarkDuplicates from Picard (http://picard.
sourceforge.net).
For linkage analysis, a previously described method was
used.14 Briefly, genotypes of SNPs at HapMap Phase II
loci17,18 were inferred using GATK UnifiedGenotyper19,20
with a required minimum depth of 10 reads per sample, to
produce variant call format (VCF) files. LINKDATAGEN17
produced files for linkage, including removing Mendelian
errors. To satisfy linkage equilibrium assumptions markers
were chosen so that they were approximately 0.3 cM apart
when available. Inbreeding coefficients (F) were estimated
using the FEstim21 algorithm. The estimated inbreeding
coefficients were used to generate an appropriate pedigree
with an inbreeding loop (Fig. 1) for homozygosity map-
ping. Multipoint parametric linkage analysis using exome
genotypes was performed using MERLIN22 with a fully
penetrant recessive disease model with disease allele fre-
quency 0.00001, with the pedigree described in Figure 1 for
homozygosity mapping, and the nuclear family for reces-
sive disease model mapping.
Variant detection was performed with GATK Haploty-
peCaller and variant annotation using ANNOVAR.23
Exome variants were filtered and selected according to the
following criteria for the homozygous and compound het-
erozygous recessive models: location within a linkage
region, genotypes fitting the disease model, a minor allele
frequency ≤0.01 (0.05) in the exome variant server dataset
(http://evs.gs.washington.edu/EVS/) and 1000 Genomes,24
a minor allele frequency of ≤0.05 in the Exome Aggregation
Consortium database, appearance in <10 alleles of our
in-house exome dataset, and mutation type (missense,
nonsense, coding indel or splice site variant). Compound
heterozygous variants were filtered at the gene level, where
candidate genes had to have at least two remaining variants
after filtering. Variants in the same gene were assessed pair-
wise requiring that exactly one variant was heterozygous in
the father (I:1), no more than one variant was observed in
the unaffected sibling (II:1), and not present in cis-phase as
assessed in IGV,25,26 when possible.
PCR and sanger sequencing
The PRIMA1 gene and exome variants were amplified
using gene-specific primers (Table 1) designed to the ref-
erence human gene transcripts (NCBI Gene; http://
www.ncbi.nlm.nih.gov/). Amplification reactions were
cycled using a standard protocol on a Veriti Thermal
Cycler (Applied Biosystems, Carlsbad, CA) at 60°C
annealing temperature for 1 min. Bidirectional sequencing
of all exons and flanking regions was completed with a
BigDyeTM v3.1 Terminator Cycle Sequencing Kit (Applied
Biosystems), according to the manufacturer’s instructions.
Sequencing products were resolved using an 37309 L
DNA Analyzer (Applied Biosystems). All sequencing chro-
matograms were compared to published cDNA sequence;
nucleotide changes were detected, using Codon Code
Aligner (CodonCode Corporation, Dedham, MA).
Generation and analysis of lymphoblastoid
cells
Immortalized lymphoblastoid cell lines were established
from venous blood of family members II:1 and II:3 using
Epstein–Barr virus and maintained in RPMI-1640 med-
ium supplemented with 20% fetal calf serum. RNA was
extracted from the cells using an RNeasy Minikit (Qia-
gen) and cDNA generated using a SuperScript III First-
Strand Synthesis System (LifeTechnologies, Grand Island,
NY) according to the manufacturer’s instructions. PCR
was performed as described above using oligonucleotides
designed to PRIMA1 mRNA and products were resolved
on 2% agarose gels.
Minigene assay
Minigenes were generated using Exontrap vector (MoBi-
Tec Molecular Biotechnology, Goettingen, Germany),
which includes a 50 and a 30 exon separated by a 600 bp
Table 1. Oligonucleotides used in this study.
Target Oligonucleotide (50-30)
PRIMA1 exon 1 CTGACCCTAGCCTTGCTCTC (forward)
AGGAGGGAAGGGACAGCT (reverse)
PRIMA1 exon 2 CAGCTTCTAGTTGCCTTATGGTC (forward)
CTCAGTGGATCTTCGTGGG (reverse)
PRIMA1 exon 3 CATGACCAGCTCATCCAGG (forward)
ATGTGTGTAGGAGCCCCAA (reverse)
PRIMA1 exon 4 ACTAATGGTGTCCCTGCCTC (forward)
ACCTGCTTTCCCATGTCCAC (reverse)
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intron containing a polylinker for cloning of DNA of
interest. Wild-type and mutant (c.93+2T>C) PRIMA1
fragments were amplified from genomic DNA of family
members II:1 and II:3, respectively, using PCR with the
primers 50-AGGCTTGGTTTACTAGGGTG (forward) and
50-GAGAACCAACTAGTGGGGTGGCTGCAAGA
(reverse, introduced SpeI site is highlighted in bold). The
PCR products were digested with XmaI (restriction site is
located in intron 1–2) and SpeI, and cloned into XmaI/
SpeI-digested polylinker of Exontrap vector. The resulting
minigenes contained 307 bp fragment of PRIMA1: exon 2
(124 bp) with flanking intronic sequences (83 bp of
intron 1–2 and 100 bp of intron 2–3). The minigene
sequences were confirmed by Sanger sequencing.
HEK293T cells (a human embryonic kidney cell line
stably transfected with the SV40 large T antigen) were
maintained in Dulbecco’s Modified Eagle’s Medium (Invi-
trogen, Carlsbad, CA) supplemented with 10% (v/v) fetal
bovine serum, 100 U/mL penicillin, 100 lg/mL strepto-
mycin, and 2 mmol/L glutamine. The cells were transfect-
ed with wild-type or mutant PRIMA1 minigenes, or
empty Exontrap vector, using Lipofectamine-2000TM (Invi-
trogen). Twenty-four or 48 h post-transfection the cells
were harvested and total RNA was extracted using an
RNeasy Minikit (Qiagen). cDNA was generated from
1 lg of total RNA using SuperScript III reverse transcrip-
tase and random hexamer primers (Invitrogen). PCR was
performed on the cDNA using Platinum High Fidelity
Taq (Invitrogen) with the primers binding to the 50 and
30 exons of Exontrap vector. The resulting PCR products
were analyzed by electrophoresis on a 2% agarose gel.
Results
Clinical details
Two of three siblings with unaffected parents, who were
born in the same small Italian village, were diagnosed
with NFLE and intellectual disability (Fig. 1). Both
required long-term institutional care. The 53 year-old
female proband (II:3) had a history of motor and speech
delay, short stature, ataxic gait, congenital nystagmus, and
a squint. Chromosome analysis, metabolic screening and
computed tomography (CT) were normal in childhood.
During early childhood she developed seizures that per-
sisted throughout adult life. The predominant attacks
were nocturnal hyperkinetic seizures with duration ~1–2
min and a frequency of 1–2 per week characterized by
loud vocalizations, bilateral asymmetrical limb move-
ments, often with incontinence and postictal confusion.
Occasional generalized convulsions also occurred. Exami-
nation revealed nystagmus, moderate intellectual disabil-
ity, and a broad-based gait without other specific
cerebellar signs. Video electrocephalogram (EEG) con-
firmed frontal lobe nocturnal hyperkinetic attacks, and
diurnal staring attacks thought to be behavioral. CT scans
and MRI brain showed no specific lesions; there was a
suggestion of mild cerebellar atrophy. Her clinical course
was relatively stable over the last two decades.
Her 61-year-old affected brother (II:2) shares many
clinical features with his sister. He had congenital nystag-
mus and developed epilepsy in early childhood character-
ized by monthly ~1–2-min nocturnal seizures with
vocalization, asymmetrical limb movements and postictal
drowsiness as well as brief generalized tonic-clonic sei-
zures in the early morning or late evening. Clinical evalu-
ation revealed moderate intellectual disability, nystagmus,
and a mild-ataxic gait. EEG showed slow, poorly sus-
tained posterior dominant rhythm, delta slowing, with
bifrontal epileptiform discharges. Brain CT revealed mild
cerebral and cerebellar atrophy. He required a number of
hospitalizations for poor seizure control.
Candidate gene screening
The coding regions and splice sites of three known ADN-
FLE genes – CHRNA2, CHRNA4, and CHRNB2 – were
Sanger sequenced without identification of a causal muta-
tion. The KCNT1 and DEPDC5 genes were discovered to
be causal NFLE genes only after this study commenced
and no mutation of these genes was found in the subse-
quent exome sequencing analysis.
Linkage mapping using exome data detects
multiple genomic loci
The inheritance pattern in the family was unclear
although a recessive mode appeared most likely. We per-
formed linkage analysis with a fully penetrant recessive
model using 7102 SNP markers generated from the exo-
mes of four family members (I:1, II:1, II:2 and II:3;
Fig. 1). We tested the hypothesis that the family was con-
sanguineous and FEstim analysis indicated that the par-
ents were related (F estimates 0.034, 0.021, 0.036 (SE
0.010, 0.009, 0.014) for II:1, II:2, and II:3, respectively),
with an inferred relationship of second-cousins. The
father (I:1) also showed evidence of consanguinity
(F = 0.022 [SE 0.009]), but his inbreeding loop is not rel-
evant to the detection of autozygosity for this phenotype.
Multipoint parametric linkage analysis using a pedigree
with an inferred inbreeding loop revealed multiple linkage
peaks including four with a parametric LOD score >1.5
(Fig. 2A; Table 2), and using the nuclear pedigree pro-
duced 36 regions with LOD score >0.5 (Fig. 2B; Table 3),
allowing us to exclude 98 and 74% of the autosome,
respectively.
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Exome variant analysis reveals a mutation
in the PRIMA1 gene
We generated high coverage exomes for all four family
members (Table 4). Exome variants under the linkage
peaks were filtered as described in the Methods section
where one homozygous recessive and twelve compound
heterozygous variants in one and six genes, respectively,
were identified that passed filtering (Tables 5, 6). The
homozygous variant on chromosome 14 in the PRIMA1
gene is a novel splice site mutation (c.93+2T>C) that sub-
stitutes the invariant ‘T’ allele27 of the 50 splice site of the
intron following exon 2 (the first coding exon) for a ‘C’
(Fig. 2C). This mutation is predicted to cause skipping of
exon 2 during PRIMA1 pre-mRNA splicing as supported
by splice prediction software (Analzyer Splice Site Tool,
Tel Aviv University, Israel) indicating the splicing
machinery will fail to recognize the mutant splice site.
Since individual I:2 was not exome sequenced, her c.93+2
genotype was determined by Sanger sequencing of genomic
DNA derived from her breast tissue (Fig. 1). Although
PRIMA1 lymphocyte expression was not reported in pub-
licly available expression databases, we obtained a fresh
blood sample from affected (II:3) and unaffected (II:1)
sibs and generated lymphoblastoid cell lines (LCLs) to
check for mRNA expression. However, PRIMA1 expres-
sion was not detected in cell lines from either family
member (data not shown).
Table 2. Chromosomal regions with LOD > 1.5 identified by homozygosity mapping.
Chr
Flanking genetic markers
Beginning of region End of region
Peak LOD
Marker Base pairs cM Marker Base pairs cM Parametric
7 rs17241389 83,764,309 101.32 rs2106432 92,970,847 107.25 1.8970
8 rs3935174 131,165,086 144.37 rs2292781 141,559,358 161.5 1.9264
13 rs7997193 56,574,363 55.7 rs9541675 69,559,370 63.66 1.5088
14 rs3818263 92,588,002 90.12 rs1047351 99,876,505 106.71 1.9263
chr, chromosome; cM, centimorgan.
B
A
C
Figure 2. Whole exome sequencing and linkage mapping. (A) Genome-wide parametric LOD scores generated using exome data assuming an
autosomal recessive inheritance model with consanguinity. Multiple linkage peaks were detected with the highest LOD score of ~1.93 detected
for regions on chromosomes 8 and 14. (B) Genome-wide parametric LOD scores generated using exome data assuming an autosomal recessive
inheritance model with the nuclear pedigree. Multiple linkage peaks were detected with the highest LOD score of ~0.71. (C) Representative
sequence chromatograms of c.93+2 genotypes in the family – the results for three individuals are shown.
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None of the six genes containing compound heterozy-
gous variants (Table 6) are convincing candidates. For
LOC120824, nothing is known while little functional
information is available for DNHD1, other than it
encodes the dynein heavy chain domain 1 that is pre-
dicted to be a chaperone or mitotic protein,28 and
CLEC16A, other than it is a susceptibility gene for diabe-
tes, multiple sclerosis, and immunoglobulin A defi-
ciency.29 ABCA8 is a xenobiotic transporter gene of the
ABC subfamily that transport foreign chemicals, such as
antibiotics, across cellular membranes by ATP hydroly-
sis.30 PPL encodes periplakin that is expressed in brain
but its known function is to associate with desmosomal
plaques and keratin filaments in the epidermis, and mice
null for the gene are phenotypically normal.31 A tumor
suppressor gene, LLGL1 regulates basal protein targeting
in both embryonic and larval Drosophila neuroblasts,32
and newborn homozyous knockout Lgl1 pups develop
severe hydrocephalus and die neonatally.33
Confirmation of PRIMA1 exon skipping
in vitro
Since PRIMA1 was not expressed in lymphocytes and we
did not have access to other tissues from family members,
we examined the effect of the mutation using a minigene
Table 3. Chromosomal regions with LOD > 0.5 identified by recessive disease model mapping.
Chr
Flanking genetic markers
Beginning of region End of region
Peak LOD
Marker Base pairs cM Marker Base pairs cM Parametric
1 rs12127966 4,234,940 9.937 rs6689940 6,281,090 15.914 0.7084
1 rs2803155 77,958,837 106.42 rs541628 117,256,763 147.404 0.7085
1 rs11264818 157,742,017 168.503 rs10800465 162,310,313 175.048 0.7085
2 rs6716306 102,014,754 120.716 rs13427053 105,186,053 123.054 0.7083
2 rs13020764 125,664,440 144.186 rs4525749 139,069,573 157.912 0.7085
2 rs6436746 228,893,467 242.144 rs10169296 236,766,825 256.37 0.7085
3 rs2674533 651,876 0.799 rs1562080 4,025,703 10.174 0.7083
3 rs9873219 77,354,463 104.709 rs9873303 115,396,528 125.341 0.7085
3 rs7633364 185,218,549 196.279 rs2280268 193,031,926 213.549 0.7085
6 rs9448707 80,139,318 88.977 rs9391249 105,343,433 108.871 0.7085
7 rs1429745 85,005,512 101.86 rs4727629 105,467,529 118.864 0.7085
8 rs17745485 417,836 0.383 rs5020778 13,596,612 30.377 0.7084
8 rs7836437 70,840,655 87.368 rs10098671 87,243,097 100.132 0.7085
8 rs7830253 108,185,786 119.456 rs16899173 124,995,902 133.622 0.7084
8 rs13278110 131,097,405 144.368 rs11167136 143,310,815 164.929 0.7085
9 rs4237150 4,290,085 11.461 rs4741080 11,009,202 25.175 0.7085
9 rs3824372 17,752,252 36.778 rs17781724 24,538,114 46.728 0.7085
9 rs7850371 28,164,681 53.241 rs12238895 80,827,249 78.289 0.7085
9 rs10988451 101,741,666 103.679 rs4240435 132,385,003 142.573 0.7085
10 rs1769236 734,229 0.192 rs4749890 9,739,317 21.719 0.7085
10 rs17685697 28,620,873 51.218 rs1961333 45,612,064 64.193 0.7079
10 rs1547843 91,738,263 117.5 rs4463806 115,597,993 140.176 0.7085
11 rs325606 6,243,982 12.483 rs9787738 11,161,897 20.532 0.7085
11 rs17609863 29,293,934 46.016 rs11601550 133,707,109 155.667 0.7085
12 rs4765268 126,133,693 151.605 rs12300232 133,648,090 174.669 0.7085
14 rs1984536 26,637,188 18.918 rs11623717 54,414,132 48.798 0.7085
14 rs7150314 82,384,079 77.741 rs4448834 107,170,398 120.134 0.7085
15 rs453151 70,097,675 86.294 rs3743475 89,172,558 105.572 0.7085
16 rs7359494 310,574 0.172 rs3748980 12,875,075 29.646 0.7085
16 rs11643526 61,668,000 80.826 rs8044379 76,274,993 94.041 0.7085
17 rs11651333 11,858,949 30.461 rs11656692 31,327,572 50.541 0.7085
17 rs4128941 63,531,331 89.185 rs7211813 68,144,014 96.289 0.7085
18 rs2293517 10,784,331 32.578 rs11662426 36,920,736 56.684 0.7085
18 rs5375 74,962,810 111.193 rs9950415 77,643,034 117.589 0.5693
19 rs11881257 54,196,217 93.877 rs12691095 56,718,895 103.318 0.7085
21 rs9981410 17,450,982 5.82 rs1005164 45,680,103 58.637 0.7085
chr, chromosome; cM, centimorgan.
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assay. PRIMA1 DNA fragments containing exon 2
(124 bp) with flanking intronic sequences (wild-type and
c.93+2T>C) were amplified from the genomic DNA of
unaffected and affected family members, respectively, and
cloned into a splicing-competent minigene vector.
HEK293T cells were transfected with the minigenes and
the vector, and incubated for 24 or 48 h. Cellular RNA
was then extracted and the splicing of minigene-derived
RNA was analyzed by RT-PCR using PCR primers bind-
ing to the 50 and 30 exons of the vector. The results
revealed incorporation of exon 2 in RNA produced by
the wild-type minigene and skipping of exon 2 in RNA
produced by the mutant minigene (Fig. 3).
Re-sequencing of PRIMA1 in additional cases
We designed oligonucleotides (Table 1) to screen the
entire coding region and splice sites of the PRIMA1 gene.
Three hundred unrelated patients diagnosed with NFLE,
including 212 with Italian ancestry, were screened using
these oligonucleotides by Sanger sequencing or as part of
the exome sequencing studies. No potential recessive or
compound heterozygous mutations were detected.
Discussion
Nocturnal frontal lobe epilepsy is an important epilepsy
syndrome known to be inherited in an autosomal domi-
nant manner or to occur sporadically. Recessive inheri-
tance has not been previously recognized. Using a whole
exome and linkage analysis strategy, we discovered the
cause for ARNFLE and intellectual disability in this fam-
ily, being a mutation in the PRIMA1 gene.
Acetylcholinesterase (AChE) plays a pivotal role as a
hydrolase in the central and peripheral nervous systems
catalyzing the hydrolysis of acetylcholine (ACh) to main-
tain neurotransmitter homeostasis. Inhibition of AChE
leads to enhanced cholinergic responses due to excess
ACh over-stimulating nicotinic and muscarinic recep-
tors.34 This can alter both central and peripheral pro-
cesses, including control of respiration and seizure
activity, autonomic, and somatic motor functions. In
brain, AChE is found in its functional form as a tetramer
associated with PRIMA1 at neuronal synapses. This asso-
ciation is facilitated by interaction between the tryptophan
amphiphilic tetramerization domains on the catalytic
subunits of AChE and the proline-rich attachment domain
(PRAD) on the extracellular domain of PRIMA1.35
Perturbation of the cholinergic system has been linked
to the pathogenesis of ADNFLE, specifically the increased
sensitivity of nicotinic acetylcholine receptor (nAChR)
subunits to ACh. Dominant mutations in three receptor
subunits have been found in families segregating NFLE.5–7
This hypersensitivity was demonstrated for the a2 subunit
mutation in vitro by whole-cell recordings of HEK293
cells transfected with wild-type or mutant receptor.5 Loss
Table 4. Exome coverage statistics.
Patient Total reads
Mean
read
depth
% bases
covered
by 2
reads
% bases
covered
by 5
reads
% bases
covered
by 10 reads
I:1 2278520917 44 94 91 85
II:1 3801912357 73 96 94 91
II:2 1802808122 35 94 89 81
II:3 5292190911 102 96 94 92
Table 5. Filtered homozygous recessive exome variants under linkage
peaks.
Chr Genomic site Variant Gene Amino acid Effect
14 94,253,970 T>C PRIMA1 – Splice site
Table 6. Filtered compound heterozygous exome variants under linkage peaks.
Chr Genomic site Variant Gene Amino acid Effect
11 6,519,561 A>G DNHD1 Q>R Nonsynonymous SNV
11 6,568,866 C>T DNHD1 R>C Nonsynonymous SNV
11 48,997,336 C>T LOC120824 C>Y Nonsynonymous SNV
11 49,003,195 C>A LOC120824 C>F Nonsynonymous SNV
16 4,934,157 ->CCACCTTCTCCTTGACCT PPL V>EVKEKVV Nonframeshift insertion
16 4,945,400 CTC>- PPL E>- Nonframeshift deletion
16 11,097,073 G>C CLEC16A G>A Nonsynonymous SNV
16 11,272,419 C>A CLEC16A P>T Nonsynonymous SNV
17 18,129,027 G>A LLGL1 A>T Nonsynonymous SNV
17 18,133,277 A>C LLGL1 N>T Nonsynonymous SNV
17 66,879,927 C>T ABCA8 – Splice site
17 66,914,289 G>C ABCA8 P>R Nonsynonymous SNV
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of PRIMA1 represents a new mechanism for over-
stimulation of nAChRs via reduction in AChE activity
leading to accumulation of ACh. A severe reduction in
AChE has already been demonstrated in PRiMA knock-
out mice that lack the critical PRAD domain.34 In the
striatum, chosen because it contains the highest level of
AChE in the brain, PRiMA knockout mice only exhibit
2–3% of wild-type AChE activity despite having normal
AChE mRNA levels. The residual AChE is localized to the
endoplasmic reticulum. These data indicate that PRiMA
is critical to intracellular processing of AChE, and target-
ing it to and stabilizing it at the axon. It is noteworthy
that PRiMA is only required to anchor AChE at synaptic
junctions in the brain, and not in the muscle, consistent
with the phenotype observed in the family studied here.
The splice site mutation we found in PRIMA1 results
in skipping of the first coding exon that contains the first
93 base pairs of coding sequence. While in-frame, this
would result in loss of the first 31 amino acids of the
PRIMA1 protein, including the methionine start site and
most of the signal peptide. An alternative methionine
start site is not present until position 137, close to the
C-terminus of the 153 amino acid PRIMA1 protein. Since
the affected siblings are homozygous for the mutation,
the effect is predicted to be a complete knockout of
PRIMA1 in their cells.
We describe ARNFLE, and document a more severe phe-
notype than usually observed in dominant cases that
includes intellectual disability. Our genetic analysis reveals
the first cause for this disease being mutation of PRIMA1.
Whilst it would have been ideal to identify further indepen-
dent subjects with mutated PRIMA1, analysis of 300 other
unrelated cases was negative. However, the likely loss of
function of PRIMA1 caused by this mutation and its bio-
logical plausibility because of its effect on the cholinergic
system strongly suggest it is a novel, albeit rare, cause of
NFLE. This further highlights the role of the cholinergic
system in this characteristic nocturnal epilepsy syndrome.
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